SEC Company Response from SAB Biotherapeutics, (SABS) — Sep 26, 2025
SAB Biotherapeutics, Inc.
Date: Sept. 26, 2025 · CIK: 0001833214 · Accession: 0001193125-25-220723
AI Filing Summary & Sentiment
File numbers found in text: 333-289992
Letter
RE:
September 26, 2025
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
SAB Biotherapeutics, Inc. Registration Statement on Form S-3
File No. 333-289992
Filed September 2, 2025; amended September 22, 2025
In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to September 30, 2025 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act.
Please call Ilan Katz of Dentons US LLP at (212) 632-5556 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
SAB Biotherapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
September 26, 2025
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
RE:
SAB Biotherapeutics, Inc.
Registration Statement on Form S-3
File No. 333-289992
Filed September 2, 2025; amended September 22, 2025
In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to September 30, 2025 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act.
Please call Ilan Katz of Dentons US LLP at (212) 632-5556 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
SAB Biotherapeutics, Inc.
/s/ Samuel J. Reich
Samuel J. Reich
Chief Executive Officer
cc:
Ilan Katz, Dentons US LLP